This 2026 consensus frames stereotactic body radiation therapy (SBRT)/stereotactic ablative radiotherapy (SABR) as a precision, high‑efficiency radical treatment for early‑stage non‑small cell lung cancer (NSCLC). The panel highlights that SBRT/SABR has become an important option particularly for patients who are medically inoperable or who decline surgery. Advances in radiotherapy technology and accumulating clinical research have expanded SBRT/SABR indications and practical applications. The consensus synthesizes domestic and international evidence alongside expert clinical experience to present a current, practice‑oriented overview. Specific trial data, outcome metrics, and comparative statistics are summarized in the full text; the PubMed abstract indicates these elements informed the consensus but does not provide numeric study results.
One core aim of the consensus is to define baseline standards to support safe, reproducible SBRT/SABR delivery. The expert group addresses recommended equipment configurations, principles of treatment planning, and quality assurance practices that promote treatment homogeneity across institutions. Emphasis is placed on leveraging modern radiotherapy hardware and software capabilities to ensure precise target localization and dose delivery. Quality assurance considerations are presented as integral to both patient safety and consistent therapeutic outcomes. The PubMed abstract does not list specific device models, numerical QA tolerances, or step‑by‑step commissioning procedures; such operational specifics are expected to be in the full consensus document.
The consensus provides refined guidance on selecting appropriate candidates for SBRT/SABR among patients with early‑stage NSCLC. It reinforces SBRT/SABR’s role for patients who cannot undergo surgery or who refuse it, and it details elements of the clinical workflow from initial assessment through follow‑up. Patient selection includes staging considerations, diagnostic confirmation, and evaluation of comorbidities that may affect treatment tolerance or outcomes. Treatment workflow recommendations encompass imaging for planning, motion management, target delineation, and multidisciplinary coordination. The document also outlines approaches to evaluate efficacy, including expected clinical endpoints and follow‑up surveillance strategies. The abstract indicates these domains are addressed but does not report specific staging cutoffs, imaging protocols, or follow‑up intervals; consult the full text for precise protocols and evaluation metrics.
Recognizing increasing use of systemic agents in lung cancer care, the consensus discusses strategies for integrating SBRT/SABR with immunotherapy/targeted therapy. The panel considers combination approaches, timing considerations, and safety management to mitigate overlapping toxicities. The guidance aims to help clinicians balance potential synergistic benefits with the need to monitor and manage adverse events related to combined modality treatment. The PubMed abstract confirms discussion of combination strategies and safety but does not include detailed sequencing recommendations, specific agent interactions, or toxicity incidence figures—these are likely provided in the full consensus text.
Special clinical situations, exemplified by central lung cancer, are specifically addressed. The consensus offers recommendations for risk assessment, treatment modification, and enhanced safety measures when lesions are adjacent to critical structures. The goal is to provide practical advice to reduce severe toxicity risk while preserving the curative potential of SBRT/SABR. The abstract identifies central tumors and other complex scenarios as a focus area; however, precise technical modifications, margin definitions, or organ‑at‑risk dose constraints are not reported in the abstract and would require review of the full article for operational detail.
This consensus statement was developed by major Chinese radiation oncology organizations, including the Radiation Oncology Branch of the Chinese Medical Association, the Chinese Society of Clinical Oncology (CSCO) Radiation Therapy Expert Committee, the Radiation Therapy Committee of the China Anti‑Cancer Association, and the Radiation Oncologist Branch of the Chinese Medical Doctor Association. Its stated purposes are to standardize clinical practice, improve treatment homogenization, facilitate collaborative research, optimize clinical decision making, and promote high‑quality implementation of SBRT/SABR in China to benefit a larger population of patients with lung cancer.
The consensus was published in Zhonghua Zhong Liu Za Zhi on 23 September 2026 (48[9]:1108–1123). PubMed lists an English abstract as well as the Chinese full text. The publication’s PMID is 42764217 and the DOI is 10.3760/cma.j.cn112152-20260313-00129. All authors declared no conflicts of interest in the PubMed record.
The PubMed abstract summarizes the consensus scope and main content areas but does not include granular technical parameters such as dose/fractionation schedules, exact QA thresholds, model‑specific equipment specs, or numeric efficacy and toxicity outcomes. Clinicians and centers seeking implementational detail should consult the full consensus text in Zhonghua Zhong Liu Za Zhi or linked full‑text sources for operational protocols, dose constraints, and procedural checklists. The consensus provides a framework for standardizing SBRT/SABR practice in early‑stage NSCLC and should be used in conjunction with local resources, institutional policies, and multidisciplinary judgment.